JP6721419B2 - エズリン由来ペプチド、およびその医薬組成物 - Google Patents

エズリン由来ペプチド、およびその医薬組成物 Download PDF

Info

Publication number
JP6721419B2
JP6721419B2 JP2016110444A JP2016110444A JP6721419B2 JP 6721419 B2 JP6721419 B2 JP 6721419B2 JP 2016110444 A JP2016110444 A JP 2016110444A JP 2016110444 A JP2016110444 A JP 2016110444A JP 6721419 B2 JP6721419 B2 JP 6721419B2
Authority
JP
Japan
Prior art keywords
peptide
seq
pharmaceutical composition
peptides
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016110444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017025055A5 (https=
JP2017025055A (ja
Inventor
ホルムズ ルパート
ホルムズ ルパート
アタウーラカノフ ラフシャン
アタウーラカノフ ラフシャン
アタウーラカノフ ルスタム
アタウーラカノフ ルスタム
サヤジャン ハチェイク
サヤジャン ハチェイク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nearmedic International Ltd
Original Assignee
Nearmedic International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nearmedic International Ltd filed Critical Nearmedic International Ltd
Publication of JP2017025055A publication Critical patent/JP2017025055A/ja
Publication of JP2017025055A5 publication Critical patent/JP2017025055A5/ja
Application granted granted Critical
Publication of JP6721419B2 publication Critical patent/JP6721419B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4735—Villin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016110444A 2015-06-01 2016-06-01 エズリン由来ペプチド、およびその医薬組成物 Expired - Fee Related JP6721419B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2015120667 2015-06-01
RU2015120667 2015-06-01

Publications (3)

Publication Number Publication Date
JP2017025055A JP2017025055A (ja) 2017-02-02
JP2017025055A5 JP2017025055A5 (https=) 2020-05-28
JP6721419B2 true JP6721419B2 (ja) 2020-07-15

Family

ID=56117690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016110444A Expired - Fee Related JP6721419B2 (ja) 2015-06-01 2016-06-01 エズリン由来ペプチド、およびその医薬組成物

Country Status (26)

Country Link
US (1) US9682140B2 (https=)
EP (1) EP3191504B1 (https=)
JP (1) JP6721419B2 (https=)
KR (1) KR101842978B1 (https=)
CN (1) CN106188267B (https=)
AU (1) AU2016203656B2 (https=)
CA (1) CA2931875C (https=)
CY (1) CY1120501T1 (https=)
DK (1) DK3191504T3 (https=)
ES (1) ES2660894T3 (https=)
GB (1) GB2546439B (https=)
HR (1) HRP20180560T1 (https=)
HU (1) HUE038737T2 (https=)
LT (1) LT3191504T (https=)
MA (1) MA39421A (https=)
MD (1) MD3191504T2 (https=)
ME (1) ME03033B (https=)
MX (1) MX377333B (https=)
PL (1) PL3191504T3 (https=)
PT (1) PT3191504T (https=)
RS (1) RS57067B1 (https=)
SG (1) SG10201604401UA (https=)
SI (1) SI3191504T1 (https=)
SM (1) SMT201800190T1 (https=)
WO (1) WO2016193285A1 (https=)
ZA (1) ZA201603723B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
CN106596977B (zh) * 2017-02-08 2018-06-08 南京医科大学第一附属医院 ezrin在制备哮喘诊断试剂中的应用
WO2021198346A2 (en) 2020-04-01 2021-10-07 Dr. Nesselhut Besitzgesellschaft Mbh Ezrin peptide 1 for use in a method of treating covid-19
CA3173136A1 (en) * 2020-04-01 2021-10-07 Thomas Nesselhut Ezrin peptide 1 for use in a method of treating covid-19
EP4313108A1 (en) 2021-03-31 2024-02-07 Pantapharm AG Ezrin peptide 1 for use in a method of treating post covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290293A (en) 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin
GB0301879D0 (en) 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
WO2007060440A2 (en) 2005-11-23 2007-05-31 Regent Research L.L.P. The use of peptides in anti-ulcer therapy

Also Published As

Publication number Publication date
SG10201604401UA (en) 2017-01-27
KR20160141673A (ko) 2016-12-09
GB2546439B (en) 2020-08-26
CA2931875A1 (en) 2016-12-01
KR101842978B1 (ko) 2018-03-29
HRP20180560T1 (hr) 2018-05-04
CN106188267A (zh) 2016-12-07
DK3191504T3 (en) 2018-04-30
CN106188267B (zh) 2020-11-06
ME03033B (me) 2018-10-20
SI3191504T1 (en) 2018-04-30
PL3191504T3 (pl) 2018-08-31
EP3191504B1 (en) 2018-01-17
LT3191504T (lt) 2018-04-10
WO2016193285A1 (en) 2016-12-08
BR102016012501A2 (pt) 2020-04-28
NZ720748A (en) 2023-09-29
ES2660894T3 (es) 2018-03-26
JP2017025055A (ja) 2017-02-02
RS57067B1 (sr) 2018-06-29
GB2546439A (en) 2017-07-19
AU2016203656A1 (en) 2016-12-15
MD3191504T2 (ro) 2018-04-30
SMT201800190T1 (it) 2018-05-02
US20160346383A1 (en) 2016-12-01
PT3191504T (pt) 2018-04-16
ZA201603723B (en) 2019-03-27
HUE038737T2 (hu) 2018-11-28
MX2016007122A (es) 2017-01-25
AU2016203656B2 (en) 2020-02-06
MA39421A (fr) 2017-07-19
EP3191504A1 (en) 2017-07-19
CA2931875C (en) 2022-06-21
GB201705990D0 (en) 2017-05-31
US9682140B2 (en) 2017-06-20
CY1120501T1 (el) 2019-07-10
MX377333B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
JP6721419B2 (ja) エズリン由来ペプチド、およびその医薬組成物
CN114835784B (zh) 抗炎肽及其用途
CN112020367B (zh) 用于治疗急性呼吸道传染病的抗病毒免疫调节剂
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
CN106749594B (zh) 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用
WO2005046569A2 (en) Pharmaceutical compositions for the treatment of sars
JP2638666B2 (ja) 血液調節ペプチド
RU2694906C2 (ru) Пептиды производные эзрина и фармацевтические композиции на их основе
TW201302214A (zh) 治療或預防皮膚癌之類鋅手指胜肽、其表現質體、及包含其之醫藥組成物
NZ720748B2 (en) Ezrin-derived peptides and pharmaceutical compositions thereof
BR102016012501B1 (pt) Peptídeo, composição farmacêutica, uso do peptídeo e uso da composição farmacêutica
JP2024545747A (ja) ペンタペプチドおよびその用途
CN108822190B (zh) 多肽及其药物组合物和用途
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
TW202116347A (zh) 肽及其作為製備治療發炎性疾病及疼痛的藥物的用途
KR20030077950A (ko) 생리활성 복합체
TW476650B (en) Use of a cytokine regulatory agent to treat rheumatoid arthritis
WO2025241148A1 (zh) 化合物及其制备方法和应用
SUSZKO-PAWŁOWSKA et al. Ovocystatin tetramer–effect on humoral immune response in SRBC-immunized mice and cytotoxic activity
CN100366633C (zh) 棕点湍蛙抗病毒多肽及其在制药中的应用
KR20230066252A (ko) 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도
CN102526710A (zh) 一种治疗猪病毒病蛋白质组合物
HK1070835A1 (en) Pharmaceutical compositions for the treatment of sars
WO2014148489A1 (ja) 環状ペプチド
HK1070835B (en) Pharmaceutical compositions for the treatment of sars

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200417

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200417

TRDD Decision of grant or rejection written
A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200519

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200618

R150 Certificate of patent or registration of utility model

Ref document number: 6721419

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees